Compare Abeona Therapeutics Inc (ABEO) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs State Street PDR S&P Retail ETF — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while State Street PDR S&P Retail ETF trades at $85.74. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, State Street PDR S&P Retail ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | XRT | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $90.88 |
52-Week Low | $4.17 | $77.28 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
XRT trades at $87.62, down 0.5% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF faces mixed sentiment with recent downgrades citing macroeconomic headwinds despite strong retail sales data. Current price sits near key support at $87 with resistance at $88.
Outlook remains cautious as attractive valuation metrics conflict with consumer sentiment concerns. Investment opportunity exists in retail sector exposure but risks include negative real wage growth and high energy prices pressuring consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
